Technical Analysis for C4XD - C4X Discovery Holdings plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 5.26% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.86% | |
| Inside Day | Range Contraction | 2.86% | |
| Wide Bands | Range Expansion | 2.86% | |
| Multiple of Ten Bearish | Other | -4.51% | |
| Wide Bands | Range Expansion | -4.51% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| NR7 | Range Contraction | -6.98% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 22 minutes ago |
| Down 5% | 22 minutes ago |
| Down 3% | 22 minutes ago |
| Down 2% | 22 minutes ago |
| Down 1% | 22 minutes ago |
Get this analysis on your stocks daily!
C4X Discovery Holdings plc Description
C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biopharmaceutical Biology Drug Discovery Autoimmune Diseases Diabetes Health Sciences Chronic Obstructive Pulmonary Disease Autoimmune Disease Psoriasis Inflammatory Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.985 |
| 52 Week Low | 7.35 |
| Average Volume | 737,797 |
| 200-Day Moving Average | 14.48 |
| 50-Day Moving Average | 11.57 |
| 20-Day Moving Average | 10.26 |
| 10-Day Moving Average | 9.33 |
| Average True Range | 1.48 |
| RSI (14) | 39.02 |
| ADX | 26.45 |
| +DI | 14.73 |
| -DI | 24.47 |
| Chandelier Exit (Long, 3 ATRs) | 10.59 |
| Chandelier Exit (Short, 3 ATRs) | 11.80 |
| Upper Bollinger Bands | 14.20 |
| Lower Bollinger Band | 6.32 |
| Percent B (%b) | 0.28 |
| BandWidth | 76.80 |
| MACD Line | -0.90 |
| MACD Signal Line | -0.82 |
| MACD Histogram | -0.0764 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.32 | ||||
| Resistance 3 (R3) | 11.49 | 10.75 | 10.86 | ||
| Resistance 2 (R2) | 10.75 | 10.04 | 10.66 | 10.70 | |
| Resistance 1 (R1) | 9.65 | 9.61 | 9.28 | 9.47 | 10.55 |
| Pivot Point | 8.90 | 8.90 | 8.71 | 8.81 | 8.90 |
| Support 1 (S1) | 7.80 | 8.20 | 7.43 | 7.63 | 6.55 |
| Support 2 (S2) | 7.06 | 7.76 | 6.97 | 6.40 | |
| Support 3 (S3) | 5.96 | 7.06 | 6.24 | ||
| Support 4 (S4) | 5.78 |
